Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 48
Healthy volunteers: yes

Brief summary:
LY2944876 is an investigative drug for the treatment of Type 2 Diabetes Mellitus. Part A of the study will assess the safety and tolerability of single doses of LY2944876 in Japanese participants. Participation is expected to last up to about 7 weeks, not including screening.

Part B of the study will investigate the safety and tolerability of multiple doses of LY2944876 in non Japanese participants. Participation is expected to last up to about 8 weeks, not including screening.

All doses will be administered as injections into the fatty layer just beneath the skin.

Screening is required within 28 days prior to the start of the study. All participants will attend a post study safety assessment approximately 6 weeks after their final dose.

Detailed description:

Arms:
arm 1: Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1 arm 2: Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1 arm 3: Placebo matching LY2944876 administered once daily SC on Days 1-7 arm 4: 40 mg LY2944876 administered once daily SC on Days 1-7 arm 5: Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12 arm 6: LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC

Interventions: intervention 1: LY2944876 intervention 2: Placebo
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC

Protocol document: